Related Experiment Video

Updated: Jul 17, 2026

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
08:25

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Published on: April 7, 2015

[Implication of dexamethasone adjunctive therapy after the onset of cerebral vasculitis in Streptococcus pneumoniae

N Lefebvre1, A-C Carre, X Delabranche

  • 1Service de Réanimation Médicale, Centre Hospitalier de Mulhouse, 20, rue du Docteur-René-Laennec, 68070 Mulhouse cedex 01, France. n.lefebvre@yahoo.fr

Medecine Et Maladies Infectieuses
|February 3, 2007
PubMed

Insights

Adjunctive dexamethasone in pneumococcal meningitis is generally safe, but this case report highlights a rare risk of cerebral vasculitis. Stopping treatment may trigger a rebound effect, necessitating protocol review.

Area of Science:

  • Neurology
  • Infectious Diseases
  • Pharmacology

Background:

  • Adjunctive dexamethasone is recommended for bacterial meningitis to reduce inflammation and neurological sequelae.
  • Pneumococcal meningitis is a severe infection requiring prompt antibacterial therapy and supportive care.
  • Adverse effects of dexamethasone in this context are considered rare.

Observation:

  • A 49-year-old male presented with fever and altered mental status, diagnosed with Streptococcus pneumoniae meningitis.
  • Initial treatment included antibiotics and adjunctive dexamethasone, leading to a favorable response.
  • Cerebral vasculitis was diagnosed on day 9 via CT scan after neurological deterioration.

Findings:

  • The patient experienced a secondary neurological worsening after dexamethasone treatment was discontinued.
  • This suggests a potential rebound inflammatory effect upon cessation of adjunctive dexamethasone.
  • Cerebral vasculitis was confirmed as the cause of neurological decline.

Implications:

  • This case suggests a potential, albeit rare, risk of cerebral vasculitis associated with adjunctive dexamethasone in pneumococcal meningitis.
  • The observed rebound effect upon treatment cessation warrants further investigation.
  • Clinical protocols for adjunctive dexamethasone in bacterial meningitis may require re-evaluation to mitigate such risks.

Related Concept Videos

Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
Bacterial Meningitis01:24

Bacterial Meningitis

Bacterial meningitis is a severe infectious disease involving inflammation of the meninges, the protective membranes surrounding the brain and spinal cord. It occurs when pathogenic bacteria cross the blood–brain barrier and enter the cerebrospinal fluid. Common causative organisms include Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b, Listeria monocytogenes, and Escherichia coli K1. The exact route of entry varies by pathogen and host condition.Routes of Entry...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Streptococcal Pharyngitis01:27

Streptococcal Pharyngitis

Streptococcal pharyngitis, commonly known as “strep throat,” is an acute infection of the oropharyngeal tissues caused by the Gram‑positive Group A Streptococcus (Streptococcus pyogenes). Transmission occurs primarily through respiratory droplets expelled during coughing, sneezing, or talking.Mechanisms of Host Entry and Immune EvasionUpon entering the host, S. pyogenes adheres to the mucosal epithelial cells of the pharynx via surface proteins, notably lipoteichoic acid and the antiphagocytic...